Stock Analiz

Immunome Inc. (IMNM) financials: revenue, earnings and cash flow

Fiscal 2019–2025 · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$212M, a net margin of -3060.0%; the best year in this period was 2019 with -$10M.

Free cash flow was -$201M in fiscal 2025 and positive in 0 of the 7 years shown.

The diluted share count rose 7885% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2023: $14M20232024: $9M20242025: $7M2025$7M
Net income
2019: -$10M20192020: -$18M20202021: -$25M20212022: -$37M20222023: -$107M20232024: -$293M20242025: -$212M2025-$212M
Free cash flow
2019: -$10M20192020: -$13M20202021: -$18M20212022: -$29M20222023: -$8M20232024: -$118M20242025: -$201M2025-$201M
EPS (diluted)
2019: $-9.5520192020: $-5.2620202021: $-2.1420212022: $-3.0920222023: $-5.3820232024: $-5.0020242025: $-2.432025$-2.43

Income statement

Fiscal year2025202420232022202120202019
Revenue$7M$9M$14M————
Gross profit———————
Operating income-$224M-$306M-$110M-$37M-$25M-$12M-$10M
Net income-$212M-$293M-$107M-$37M-$25M-$18M-$10M
EPS (diluted)$-2.43$-5.00$-5.38$-3.09$-2.14$-5.26$-9.55
R&D$177M$130M$23M$23M$14M$7M$9M
Revenue growth−23.2%−35.5%—————

Cash flow

Fiscal year2025202420232022202120202019
Operating cash flow-$191M-$111M-$8M-$29M-$18M-$12M-$10M
Capital spending-$10M-$7M-$831000-$248000-$79000-$586000-$233000
Free cash flow-$201M-$118M-$8M-$29M-$18M-$13M-$10M
Dividends paid$0$0$0$0$0$0$0
Buybacks———————
Stock-based pay$26M$16M$6M$5M$3M$621000$14000

Balance sheet

Fiscal year2025202420232022202120202019
Cash$653M$217M$138M$20M$49M$40M$3M
Debt$4M$5M$2M—$500000$500000—
Equity$634M$181M$120M$17M$48M$41M-$36M
Total assets$683M$240M$149M$24M$58M$45M$5M
Shares (diluted)87M59M20M12M12M3M1M

Margins and returns

Fiscal year2025202420232022202120202019
Gross margin———————
Operating margin-3228.8%-3382.4%-781.4%————
Net margin-3060.0%-3240.4%-761.9%————
FCF margin-2890.1%-1304.8%-59.9%————
ROIC-27.7%-129.9%-71.2%-175.0%-40.9%-23.2%—
ROE-33.5%-161.7%-89.1%-221.6%-51.3%-43.1%29.3%

Frequently asked questions

What is Immunome’s annual revenue?

$7M in fiscal 2025.

How much profit does Immunome make?

Net income was -$212M in fiscal 2025 (net margin -3060.0%).

Is Immunome’s revenue growing?

No: revenue fell 23.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.